For US Healthcare Professionals

Getting Patients Started

Krystal Connect provides personalized patient support for your patients during their VYJUVEK treatment journey

The first step to getting your patients started on VYJUVEK via Krystal Connect is to download and fill out the Krystal Connect Enrollment Form.

Download Form
Krystal Connect™ logo

To contact Krystal Connect, please call 1-844-5-KRYSTAL or use our Connect With Us form.

Services Include:

Educating patients about VYJUVEK™

Educating patients about VYJUVEK and living with dystrophic epidermolysis bullosa (DEB)

  • Answer patient questions about VYJUVEK
  • Provide resources and help connect patients with programs about DEB and VYJUVEK
Assist with the insurance process

Providing insurance coverage support

  • Assist with the insurance process, including benefits investigation and prior authorizations
  • Informing patients about potential financial assistance options and eligibility requirements as needed
Supporting treatment logistics

Supporting with treatment logistics

  • Helping patients evaluate appropriate administration site options, either in a healthcare professional setting or in a home setting
  • Sharing information with patients about what to expect, and helping coordinate weekly treatments

Krystal Biotech has partnered with Option Care Health® to provide convenient in-home weekly VYJUVEK administration to your patients.

Community Education Liaisons (CELs)
  • For in-home administration, your patient's Krystal Connect™ Patient Access Liaison (PAL) will work together with Option Care Health to guide your patient through each step of the process
  • Option Care Health will help obtain insurance authorization, coordinate weekly deliveries of VYJUVEK to your patient's house, and provide weekly in-home nurse visits to apply VYJUVEK
Patient Access Liaisons (PALs)
  • Option Care Health provides all auxiliary supplies needed for treatment with VYJUVEK including gloves, scissors, and the hydrophobic dressings to be applied after administration. They also provide resealable plastic bags and a sharps container for disposal of used supplies

View Additional Helpful Forms and Resources

Discover Resources
INDICATION AND USAGE

VYJUVEK is a topical gel indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII (COL7A1) gene.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds for approximately 24 hours following treatment. Wear protective gloves when assisting subjects with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.

Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.

Dispose all materials (e.g., vial, syringe, needle, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard bag or container.

ADVERSE REACTIONS

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.


IMPORTANT SAFETY INFORMATION
INDICATION AND USAGE

VYJUVEK is a topical gel indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII (COL7A1) gene.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds for approximately 24 hours following treatment. Wear protective gloves when assisting subjects with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.

Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.

Dispose all materials (e.g., vial, syringe, needle, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard bag or container.

ADVERSE REACTIONS

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.